The Foundation: Understanding Metabolism to Develop New Therapies
Hunger, satiety, blood glucose, and body weight are not controlled by a single hormone. Different signals from the gut, adipose tissue, liver, and pancreas continuously provide the brain with information about the body’s metabolic state. This insight led to a new therapeutic approach: drugs that mimic several metabolic signals at the same time. These so-called polyagonists activate multiple receptors and can thereby influence blood glucose regulation, appetite, and body weight simultaneously.
Several scientific contributions paved the way for this approach and for modern treatments for obesity and type 2 diabetes:
Prof. Svetlana Mojsov identified the sequence of the biologically active form of GLP-1, making a major contribution to the discovery of GLP-1 as an incretin. GLP-1 is a gut hormone that regulates insulin secretion after food intake. Matthias Tschöp and Prof. Richard DiMarchi (Indiana University Bloomington), in turn, developed drugs that target multiple hormone receptors simultaneously.
The award-winning research represents a key milestone in a scientific journey that continues to shape new therapeutic approaches for obesity and type 2 diabetes.
The Future: Making Metabolic Therapies More Precise
Building on the development of polyagonists, current research at Helmholtz Munich is taking this concept one step further. Researchers are exploring hybrid drugs that act on several metabolic pathways at once. They can also carry additional therapeutic components directly to the cells where they are needed. This could make future treatments for obesity and diabetes more targeted. So far, the approach has been studied in mice, and further research is needed to determine whether it can also work in humans
Broermann Award Recognizes a New Therapeutic Principle
The Broermann Medical Innovation Award comes with prize money of one million euros and annually recognizes scientific achievements that advance medical innovation and contribute to improving patient care. Candidates undergo an international review process.
In 2026, the award goes to the research trio Svetlana Mojsov of Rockefeller University, Richard DiMarchi of Indiana University, and Matthias Tschöp, now President of LMU Munich. The award thus brings together different contributions to the development of modern metabolic therapies: research on biologically active GLP-1, the development of hormone-based drugs, and the concept of therapeutically combining multiple metabolic signals in a single molecule.